Kazia Therapeutics Limited is evaluating Paxalisib in combination regimens for advanced triple negative breast cancer through a Phase 1b trial.
2 reports, 2 independent
Updated Sep 1
Gone quiet
- Reports
- 2
- Developments
- 4
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kazia Therapeutics Limited is evaluating Paxalisib in combination regimens for advanced triple negative breast cancer through a Phase 1b trial.
How it developed
Newest first. Tap a step to see who reported it.- Sovargen Co., Ltd. licensed the drug Paxalisib from Kazia Therapeutics Limited.Sub-event
Financing supports paxalisib studies.1 source
- Kazia Therapeutics Limited announced clinical trial updates from Sydney on May 26, 2026.Sub-event
Phase 1b trial initiated for Paxalisib combination therapy targeting advanced triple negative breast cancer.1 source